Skip to main content

Advertisement

Table 1 Benchmark for secondary efficacy endpoints

From: A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis

A. Tinea lesions scoring19
Score Description
0 Absent
1 Mild
2 Moderate
3 Severe
4 Very severe
B. Scoring Clinical Index for Onychomycosis (SCIO)18 
Score Grade Description
0 None • No infection
1 Mild • Depth of involvement <1/3 • Scaling/ hyperkeratosis absent or <1 mm • Discolouration of nail
2 Moderate • Depth of involvement 1/3 to 2/3 • Scaling/ hyperkeratosis 1–2 mm • Acute Paronychia [acute inflammation surrounding nail(s)] • Nail plate dystrophy up to 50%.
3 Severe • Depth of involvement >2/3 • Scaling/ hyperkeratosis >2 mm • Chronic Paronychia [chronic inflammation surrounding nail(s)] • Nail plate dystrophy >50%
C. Investigator Global Assessment (IGA) response20
Score Response Description
5 Cleared 100% remission except residual manifestations
4 Excellent 90–99% improvement
3 Good 50–89% improvement
2 Fair 25–49% improvement
1 Poor <24% improvement
0 Worse deterioration from baseline
  1. Tinea lesions scoring [19] (A). Onychomycosis scoring - Scoring Clinical Index for Onychomycosis (SCIO) [18] (B). Investigator Global Assessment (IGA) response [20] (C)